Immunovant Announces Pricing of $75.0 Million Underwritten Offering of Common Stock
04 oct. 2022 08h45 HE
|
Immunovant
NEW YORK, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company committed to enabling normal lives for people with autoimmune diseases, today...
Immunovant Announces IMVT-1402, a Next Generation Anti-FcRn
28 sept. 2022 10h45 HE
|
Immunovant
In animal studies, deep IgG lowering similar to batoclimab with no or minimal impact on albumin and low-density lipoprotein (LDL) was observed. Plan to submit IND and initiate Phase 1 study in early...
Immunovant to Present at Roivant Investor Day on September 28th
21 sept. 2022 08h00 HE
|
Immunovant
NEW YORK, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company committed to enabling normal lives for people with autoimmune diseases, today...
Immunovant to Present at the H.C. Wainwright 24th Annual Global Investment Conference on September 14th
09 sept. 2022 08h00 HE
|
Immunovant
NEW YORK, Sept. 09, 2022 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company committed to enabling normal lives for people with autoimmune diseases, today...
UPDATE -- Immunovant Announces Two New Development Programs for Batoclimab
07 sept. 2022 07h11 HE
|
Immunovant
Plan to initiate a Pivotal Phase 2b trial in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in the second half of 20221 with initial results from open-label period 1 expected in the first...
Immunovant Announces Two New Development Programs for Batoclimab
07 sept. 2022 06h30 HE
|
Immunovant
Plan to initiate a Pivotal Phase 2b trial in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in the second half of 20221 with initial results from open-label period 1 expected in the first...
Immunovant to Host Investor Webcast to Announce Two New Indications for Batoclimab on September 7, 2022
24 août 2022 08h00 HE
|
Immunovant
NEW YORK, Aug. 24, 2022 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, will...
Immunovant Reports Financial Results and Recent Business Updates for the Quarter Ended June 30, 2022
05 août 2022 07h00 HE
|
Immunovant
NEW YORK, Aug. 05, 2022 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, today...
Immunovant Achieves Alignment with FDA on Plans for Phase 3 Clinical Trials of Batoclimab in Thyroid Eye Disease and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2022
08 juin 2022 07h00 HE
|
Immunovant
Immunovant plans to initiate two placebo-controlled Phase 3 clinical trials of batoclimab in thyroid eye disease (TED) in the second half of calendar year 2022 with top-line data expected for both in...
Immunovant to Report Fourth Quarter and Full Year 2022 Financial Results on June 8, 2022
06 juin 2022 16h47 HE
|
Immunovant
NEW YORK, June 06, 2022 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, today...